“…Several possible mechanisms may be in the background of infusion reactions including cytokine release (immune cell hyperactivation, direct apoptosis, complement-mediated lysis, antibody-dependent cellular toxicity), IgE-mediated hypersensitivity reactions to IFX, IgG anaphlyaxis, complement activation, or direct mast cell degranulation [13][14][15]. The most frequent symptoms of infusion reaction are pruritus, flushing, dyspnea, chest discomfort, hypertension, myalgia, nausea, urticaria, headache, rash, and dizziness [16]. Although there is no specific guideline for the treatment of IFX-related infusion reactions, according to therapeutic recommendations based on case reports and expert opinions, temporary attenuation of the infusion rate or temporary interruption of the infusion with the administration of medications for symptom control are usually eligible.…”